News in brief

Coffee colour…

17 Jul 2015 - 12h22 | By INSERM PRESS OFFICE | Health technologies

Birthmarks, café au lait spots—although usually harmless (over 10% of the population has one or two), the presence of more than 5 of them in a child can conceal a hereditary disease, neurofibromatosis type 1 (NF1).

This is one of the most common genetic diseases (affecting 1 in 3,000 individuals). Until now, the molecular mechanisms associated with altered skin pigmentation were poorly understood, particularly since few appropriate models have been developed in the laboratory.

Inserm researchers at I-Stem (Institute for Stem Cell Therapy and Exploration of Monogenic diseases) have developed a model reproducing in vitro the hyperpigmentation associated with type 1 neurofibromatosis  from embryonic stem cells carrying the mutation responsible for this disease[1].

By establishing a protocol for differentiating these cells into melanocytes (the cells in the skin that can produce the melanin that gives it colour), the researchers were able to find the cause of generalised hyperpigmentation and formation of “café au lait” spots. The loss of neurofibromin expression in these NF1 melanocytes leads to a cascade of dysregulation. First, dysregulation of the AMPc and ERK signalling pathways, followed by dysregulation of the transcription factor MITF, and ultimately, increased expression of the enzymes involved in melanin production.

To correct this, the researchers used pharmacological inhibitors specific for these different signalling pathways, and were able to restore the cells to normal pigmentation levels.

This hyperpigmentation defect could be corrected by single small molecules (such as kojic acid, which is already contained in skin creams or lotions for lightening the skin), demonstrating the potential of pluripotent stem cells as a model for the study of pigmentation disorders.

The researchers now plan to identify and characterise the molecular mechanisms associated with other pigmentation-related conditions to find new therapeutic strategies, which are currently based on the use of mouse models, in which the melanocytes do not have the same location as in humans.

[1] These stem cells represent an unlimited source of cells that can theoretically differentiate into all the types of cells in the body, thus making it possible to demonstrate pathological phenotypes.
Mélanocytes

Melanocytes (cells producting melanin) © Inserm/Baldeschi, Christine

TO CITE THIS POST :
Inserm press room Coffee colour… Link : http://presse.inserm.fr/en/coffee-colour/19962/
Medias
Researcher Contact

Christine Baldeschi
Inserm Unit 861 “Stem cells Institute for the treatment and the study of monogenic diseases (I-STEM)”
+ 33 (0) 1 69 90 85 33
cbaldeschi@istem.fr

Press Contact

presse@inserm.fr

Sources

In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells
Jennifer Allouchea,b, Nathalia Bellonc,d,e, Manoubia Saidanid, Laure Stanchina-Chatroussed, Yolande Massond, Anand Patwardhanf,g, Floriane Gilles-Marsensf,g, Cédric Delevoyef,g,h, Sophie Dominguesd, Xavier Nissand, Cécile Martinata,b, Gilles Lemaitrea,b, Marc Peschanskia,b, and Christine Baldeschia,b

a INSERM U-861, Institut des cellules Souches pour le Traitement et l’Etude des Maladies monogéniques (I-Stem) I-Stem, Association Française contre les Myopathies (AFM), 91030 Evry Cedex, France;
b Université d’Evry Val d’Essonne (UEVE) U-861, I-Stem, AFM, 91030 Evry Cedex, France;
c Department of Dermatology, Reference Center for Dermatologic Diseases, Paris Descartes–Sorbonne Paris Cité University, 75015 Paris, France;
d Centre d’Etude des Cellules Souches (CECS), I-Stem, AFM, 91030 Evry Cedex, France;
e Institut Imagine, Necker-Enfants Malades Hospital, 75015 Paris, France;
f Institut Curie, Paris Sciences et Lettres Research University, F-75248 Paris, France;
g Structure and Membrane Compartments, CNRS UMR 144, F-75248 Paris, France;
h Cell and Tissue Imaging Facility, CNRS UMR 144, F-75248 Paris, France

PNAS, 6 july 2015

fermer
fermer
RSS Youtube